Breaking News

Boehringer's AML Drug Gains Orphan Status

April 17, 2014

Volasertib being evaluated in patients with limited treatment options

Boehringer Ingelheim’s volasertib for acute myeloid leukemia (AML) has been granted Orphan Drug Designation by the FDA and European Commission. Volasertib is being evaluated in a Phase III trial for the treatment of patients aged 65 or older, with previously untreated AML, who are ineligible for intensive remission induction therapy.
Volasertib is an investigational compound that inhibits Plk1 enzymes, which regulates cell division and can result in prolonged cell cycle arrest, ultimately leading to cell death. AML is an aggressive cancer of the bone marrow and blood and has one of the lowest survival rates of all leukemias.
In both the U.S. and EU, Orphan Drug Designation is a status given to investigational compounds intended to treat a rare disease or condition that has limited treatment options.

blog comments powered by Disqus
  • Drug Delivery Challenges

    Shikha P. Barman, Integral BioSystems, LLC||October 7, 2015
    Sustained delivery formats for the treatment of eye disease

  • Differentiate By Being Specific

    Paul Shields and Angelo P. Consalvo, Enteris BioPharma||October 7, 2015
    Why nimble niche CMOs may be a better choice

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market